2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy.

      The American Journal of Pathology

      Animals, Antineoplastic Agents, therapeutic use, Cell Transformation, Neoplastic, Enzyme Inhibitors, Humans, Metalloendopeptidases, antagonists & inhibitors, metabolism, Neoplasm Metastasis, Proprotein Convertases, Subtilisins, physiology

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The mammalian subtilisin/kexin-like proprotein convertase (PC) family has been implicated in the activation of a wide spectrum of proteins. These proteins are usually synthesized as inactive precursors before their conversion to fully mature bioactive forms. A large majority of these active proteins such as matrix metalloproteases, growth factors, and adhesion molecules are crucial in the processes of cellular transformation, acquisition of the tumorigenic phenotype, and metastases formation. Inhibition of PCs significantly affects the malignant phenotype of various tumor cells. In addition to direct tumor cell proliferation and migration blockade, PC inhibitors can also be used to target tumor angiogenesis. In this Review article we discuss a number of recent findings on the clinical relevance of PCs in cancer patients, their implication in the regulation of multiple cellular functions that impact on the invasive/metastatic potential of cancer cells. Thus, PC inhibitors may constitute new promising agents for the treatment of multiple tumors and/or in adjuvant therapy to prevent recurrence.

          Related collections

          Author and article information

          Journal
          12057895
          1850825
          10.1016/S0002-9440(10)61140-6

          Comments

          Comment on this article